Hangzhou AGS MedTech Co. Ltd. A

Anjie Si disclosed its 2026 semi-annual report, with net profit attributable to shareholders of the listed company reaching 118 million yuan in the first half, down 6.27% year-on-year. The company achieved operating revenue of 302 million yuan in the same period, a slight decline of 0.28% year-on-year. Basic earnings per share stood at 1.4565 yuan.

Anjie Medical has released its 2026 semi-annual report, with attributable net profit for the first half reaching approximately 118 million yuan, a year-on-year decline of 6.27%. Operating revenue for the same period was about 302 million yuan, down 0.28% year-on-year. The company's main business revenue was approximately 297 million yuan, a year-on-year decrease of 0.97%, of which domestic market sales revenue was about 95.7881 million yuan, down 30.32% year-on-year, and overseas market sales revenue was about 201 million yuan, up 23.81% year-on-year. Anjie Medical is engaged in the research, development, production and sales of minimally invasive endoscopic diagnosis and treatment devices, with its main products applied in the field of digestive endoscopy.

Angelalign released its 2026 half-year report, showing net profit attributable to the parent company fell 6.3% year-on-year to 118 million yuan in the first half. Operating revenue was 302 million yuan, down 0.3% year-on-year. Deducted non-recurring net profit attributable to the parent was 99.54 million yuan, down 10.7%. Net operating cash flow was 143 million yuan, up 89.5%. Second-quarter net profit attributable to the parent was 61.33 million yuan, down 12.1% year-on-year. The company continues to focus on the research, development, production and sales of minimally invasive endoscopic diagnostic and therapeutic devices. Domestic market sales revenue declined, while overseas market sales revenue achieved growth.